Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhongze In-licenses CNS Candidate for Schizophrenia and Parkinson's

publication date: Mar 2, 2022

Shanghai Zhongze Therapeutics in-licensed a CNS candidate from Digestome Therapeutics, a San Francisco biotech. DGX-001 is a oral first-in-class candidate designed to stimulate the central nervous system via the gut-brain-axis using the vagus nerve. The candidate is aimed at treating negative symptoms and cognitive impairment in schizophrenia, and for non-motor symptoms in Parkinson's Disease. Digestome is set to start US clinical trials of DGX-001. Zhongze has two clinical stage CNS candidates and three molecules in pre-clinical development. Terms of the agreement were not disclosed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital